Continuity Biosciences Makes Strategic Investment in PinPrint, Inc. to Enhance Drug Delivery in Cosmetics

Continuity Biosciences' Investment into PinPrint, Inc.

Continuity Biosciences, LLC, has recently executed a strategic investment in PinPrint, Inc., marking a significant move to widen its horizons beyond traditional therapeutic drug delivery into aesthetic and cosmetic applications. This collaboration promises to enhance Continuity's long-term strategic value significantly.

PinPrint, Inc. stands at the forefront of an innovative technology that specializes in high-resolution, 3D-printed microneedles. This cutting-edge technology, developed by Joseph DeSimone, PhD, a prominent chemist, inventor, and entrepreneur, has made waves in the biomedical field. Dr. DeSimone serves as the Sanjiv Sam Gambhir Chair of Translational Medicine and Chemical Engineering at Stanford University. His team has pioneered a revolutionary platform that circumvents the over-curing of resin in negative spaces, creating ultra-precise microchannels and voids. Such precision is crucial for developing micro-needle patches and microfluidic devices that have numerous applications in medicine.

The latest innovation from PinPrint is a next-generation microneedle patch designed to administer vaccines and active agents through intradermal delivery, offering a replacement for traditional syringe injections. Dr. DeSimone articulated the transformative potential of this technology, saying, "By integrating high-resolution 3D printing with advanced drug delivery, we are redefining the patient experience across all therapeutic and cosmetic categories, providing a new standard of precision, customization, and comfort."

This investment correlates with Continuity's mission to advance targeted drug delivery technologies. They are currently developing implantable nanofluidic platforms in collaboration with the Grattoni Lab at Houston Methodist Hospital, which promise zero-order release capabilities. Ramakrishna Venugopalan, PhD, co-founder and CEO of Continuity Biosciences, stressed that this strategic investment enables them to transition from implantable nanofluidic systems to non-implantable microfluidic platforms, opening avenues for more effective delivery of dermatological, aesthetic, and cosmetic agents directly within the dermis.

As part of the agreement, Venugopalan will join the board of directors at PinPrint. Renee Ryan, MBA, co-founder and CEO of PinPrint, warmly welcomed him, recognizing that his expertise and strategic leadership will be vital in redefining the possibilities of drug and vaccine delivery.

About Continuity Biosciences

Continuity Biosciences, LLC is focused on developing advanced drug delivery technologies aimed at treating chronic and complex diseases. Located in Bradenton, Florida, and with a presence in Houston, Texas, the company is dedicated to enhancing the precision and efficiency of therapeutic delivery. For more information, please visit www.continuitybiosciences.com.

About PinPrint, Inc.

PinPrint, Inc. is at the forefront of revolutionizing drug and vaccine delivery through precisely engineered 3D-printed microneedle platforms. By transforming the ways medications are administered, PinPrint aims to improve patient outcomes and comfort in both therapeutic and aesthetic applications.